EML4‑ALK mutant murine lung cancer cell line

A novel syngeneic EML4-ALK mutant murine lung cancer cell line (Y143) with orthotopic growth potential, that can serve as a useful preclinical model for evaluating tumour-host interactions, the impact of specific oncogenic alterations on the tumor microenvironment, and immunotherapeutic approaches. This cell line was derived from the primary lung tumour of a female C57BL/6 mouse […]

Contributors

Inventor Institute
Stephen Malkoski The University of Colorado Anschutz Medical Campus
Cat. #: 162389
Cancer types: Lung cancer
Research Fields: Cancer biology; Immunotherapy
Organism: Mouse
Tissue: Lung
Gender: Female
Primary citation: Nolan et al. 2020. Cancer Cell Int. 28: 20:417. PMID: 32874131
Alternate name: EML4‑ALK mutant cell line; Y143 cell line
Product description: A novel syngeneic EML4-ALK mutant murine lung cancer cell line (Y143) with orthotopic growth potential, that can serve as a useful preclinical model for evaluating tumour-host interactions, the impact of specific oncogenic alterations on the tumour microenvironment, and immunotherapeutic approaches. This cell line was derived from the primary lung tumour of a female C57BL/6 mouse harbouring the EML4-ELK gene fusion and is capable of forming orthotopic tumours in immunocompetent C57BL/6 mice. Y143 cells demonstrate the EML4-ALK genetic rearrangement as shown by PCR. In Y143 cells treatment with the EML4-ALK inhibitor crizotinib inhibits phosphorylation of AKT and ERK is inhibited in a dose dependent manner and treatment with the ALK kinase inhibitor, TAE684, inhibits growth of Y143 cells.
Gender: Female
Production details: An 8 week old C57BL/6 female mouse was treated with 30 µl of 10^6 PFU/ml Ad-EA by tracheal instillation. The Ad-EA vector has an Ad5 backbone and harbors Cas9 and guide RNAs that lead to the EML4-ALK gene fusion. When this animal was euthanized 14 week later a group of multifocal tumors 3–5 mm in size were combined and passaged into a recipient animal. For this line, tumors formed in both lung and flank; these tumors were combined and then passaged together into both lung and flank sites of recipient animals. Subsequently, the EML4-ALK mutant cell line (Y143) was established that was capable of forming orthotopic tumours in immunocompetent C57BL/6 animals.
disease: Cancer
Format: Frozen
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice
Growth medium: Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g/l d-glucose, l-glutamine, and sodium pyruvate, supplemented with 10% (v/v) fetal bovine serum and 100 μg/ml of primocin (optional)
Subculture routine: Split 90% confluent cultures 1:5 to 1:15 as required. Cells are cultured at 37°C, in a humidified incubator with 5% CO2.
Temperature: 37°C
Atmosphere: 5% CO2
Biosafety level: 1
References:

Nolan et al. 2020. Cancer Cell Int. 28: 20:417. PMID: 32874131

Related Tools for Cell lines

Cat. # Tool Name
151479 HCT 116 p300 KO [D10] Cell Line Key Info View Tool
151480 HEK293A EGFP-LC3 Cell Line Key Info View Tool
151559 MEF UNG KO Cell Line Key Info View Tool
151576 MEF RAF1 KO Cell Line Key Info View Tool
151448 CMT 167 Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.